Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

Status Terminated

Clinical Trial Summary

The purpose of this study is to assess the efficacy of sural nerve transfer and cadaveric nerve graft to re-establish corneal sensation in patients with neurotrophic keratopathy.

Clinical Trial Description

Corneal anesthesia, which can lead to visually devastating outcomes from ulceration, perforation, and scarring, can be recalcitrant to both medical and surgical treatment[1-3]. Neurotization is a revolutionary technique reported to restore corneal sensation in neurotrophic keratopathy[4-6]. Prior techniques described include direct neurotization with contralateral supraorbital and supratrochlear nerves accessed via a bicoronal incision of the scalp over the forehead[5]; nerve grafting with contralateral supratrochlear nerves accessed via a medial upper eyelid incision[6]; and sural nerve grafting to contralateral supratrochlear nerves accessed via a transverse incision over the medial upper eyelid[4]. Despite the challenges associated with these techniques (needing to subcutaneously tunnel the nerve graft over the nasal bridge or requiring a large bicoronal incision), these techniques all demonstrated efficacy in direct neurotization to improve corneal sensation in these patients. The investigators aim to assess the efficacy of this innovative surgical technique involving coaptation of the sural nerve or cadaveric nerve allograft to an intact sensory branch of the trigeminal nerve to restore corneal sensation. The investigators have previously described the anatomic feasibility of using the infraorbital nerve using a cadaveric model, of which the results were presented at the American Society of Ophthalmic Plastic and Reconstructive Society Fall meeting in 2017. Utilization of the infraorbital nerve provides advantages over existing techniques due to ease of access via a cosmetically favorable incision, large caliber with increased ability to create a perineural window, relatively short and direct tunnel with possibly more rapid neurotization, and absence of complex surrounding anatomical structures. Others have previously describe success using the contralateral and ipsilateral supraorbital nerve and supratrochlear nerve. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05809245
Study type	Interventional
Source	Stanford University
Contact
Status	Terminated
Phase	N/A
Start date	March 15, 2018
Completion date	February 12, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04485546` - Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis	Phase 4
Not yet recruiting	`NCT05927428` - Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis	Phase 2
Completed	`NCT04552730` - Nerve Growth Factor for the Treatment of Cornea Disease
Completed	`NCT04276558` - REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients	Phase 2
Recruiting	`NCT04573647` - OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
Completed	`NCT04820010` - Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Recruiting	`NCT04627571` - Corneal Nerves After Treatment With Cenegermin
Enrolling by invitation	`NCT05758753` - QST for Corneal Nerve Function	N/A
Withdrawn	`NCT05321251` - Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.	Phase 2/Phase 3
Terminated	`NCT03037450` - Miniinvasive Corneal Neurotization. A Pilot Study.	N/A
Not yet recruiting	`NCT06364657` - Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
Recruiting	`NCT05566717` - An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
Not yet recruiting	`NCT02707120` - Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis	Phase 4
Completed	`NCT01756456` - Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.	Phase 1/Phase 2
Completed	`NCT02227147` - Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK	Phase 2
Recruiting	`NCT05552261` - DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Recruiting	`NCT04909450` - Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects	Phase 1/Phase 2
Active, not recruiting	`NCT06411145` - Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.